Lehua Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lehua Shi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Xiao-Feng Zhang
Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai, People’s Republic of China
2 shared publications Anfeng Si
Department of Hepatic Surgery IV, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
1 shared publication- Bin Li
First Affiliated Hospital of Xiamen University
1 shared publication - Feng Shen
Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
1 shared publication - Feng Ye
Department of Hepatobiliary & Pancreatovascular Surgery, Oncologic Center of Xiamen; First affiliated Hospital of Xiamen University, Xiamen 361003, China
1 shared publication - Haihua Qian
Department of Anorectal Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210029, China
1 shared publication
Latest Publications
- 20 April 2013
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 33 (4) , 407-410
Value of serum AFP-L3 in predicting recurrence of hepatocellular carcinoma after hepatectomy
- 20 April 2013
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 33 (4) , 407-410
Value of serum AFP-L3 in predicting recurrence of hepatocellular carcinoma after hepatectomy
- Open Access
- 19 March 2013
- Published by Springer Nature in BMC Gastroenterology
- Vol. 13 (1) , 51
Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma
Background: Long-term outcomes of partial liver resection of hepatocellular carcinoma (HCC) remain satisfactory due to high incidences of recurrence. This study was intended to see whether preoperative transcatheter arterial chemoembolization (TACE) reduces postoperative tumor recurrences and prolongs survival of patients with resectable HCC. Methods: A computerized literature search was performed to identify relevant articles. The quality of nonrandomized comparative studies (NRCTs) was assessed using the methodological index for nonrandomized studies (MINORS). Data synthesis was performed using Review Manager 5.0 software. Results: Twenty-one studies (4 randomized controlled trials and 17 NRCTs) with a total of 3,210 participants were suitable for analysis. There was no significant difference in disease-free and overall survival at 5-year (32.1% vs. 30.0% and 40.2% vs. 45.2%), and intra- and extra-hepatic recurrence (51.2% vs.53.6% and 12.9% vs.10.3%) between patients with and without preoperative TACE. Postoperative morbidity (28.9% vs. 26.8%) and in-hospital mortality (4.1% vs. 3.1%) were also similar between the two groups. Conclusions: Preoperative TACE does not seem to improve prognosis and therefore it is prudent to recommend it as a preoperative routine procedure for resectable HCC.
- 19 March 2013
- Published by Springer Nature in BMC Gastroenterology
- Vol. 13 (1) , 51
Open AccessMeta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma
Background: Long-term outcomes of partial liver resection of hepatocellular carcinoma (HCC) remain satisfactory due to high incidences of recurrence. This study was intended to see whether preoperative transcatheter arterial chemoembolization (TACE) reduces postoperative tumor recurrences and prolongs survival of patients with resectable HCC. Methods: A computerized literature search was performed to identify relevant articles. The quality of nonrandomized comparative studies (NRCTs) was assessed using the methodological index for nonrandomized studies (MINORS). Data synthesis was performed using Review Manager 5.0 software. Results: Twenty-one studies (4 randomized controlled trials and 17 NRCTs) with a total of 3,210 participants were suitable for analysis. There was no significant difference in disease-free and overall survival at 5-year (32.1% vs. 30.0% and 40.2% vs. 45.2%), and intra- and extra-hepatic recurrence (51.2% vs.53.6% and 12.9% vs.10.3%) between patients with and without preoperative TACE. Postoperative morbidity (28.9% vs. 26.8%) and in-hospital mortality (4.1% vs. 3.1%) were also similar between the two groups. Conclusions: Preoperative TACE does not seem to improve prognosis and therefore it is prudent to recommend it as a preoperative routine procedure for resectable HCC.